Royalty Pharma plc (RPRX)
Royalty Pharma plc (RPRX) is a healthcare company (biotechnology) based in the United States. The share price is $68.30, down 0.33% on the day, which values the company at $39.27B. Price as of 17 Nov 2026, 17:23 UTC, from Yahoo Finance.
Key facts
- Share price
- $68.30−0.33% today
- Market value
- $39.27B
- P/E ratio
- 44.6×last 12 months
- Forward P/E
- 11.6×
- Dividend yield
- 1.35%
- Funk Score
- 46/100
- Against its own history
- Well above its usual priceusual price $30.91
- 200-week average
- $36.6386% above
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Royalty Pharma plc in more detail
RPRX trades at 44.6× its last twelve months' earnings, 11.6× next year's expected earnings, 15.0× sales. Measured against its own history, the price is 121% above what its usual multiples would imply ($30.91) — well above its usual price. It sits 86% above its 200-week average of $36.63.
Over the last five fiscal years Royalty Pharma plc has compounded revenue 2.3% a year, earnings per share 6.2% a year. Its Funk Score is 46 out of 100 (financial strength 3.2, profitability 8.1, growth 3.5, value 3.4, each out of 10).
Worth checking: Debt is growing faster than cash flow; Heavy stock-based pay.
5 of the superinvestors tracked here hold RPRX, including Pat Dorsey (8.2% of the portfolio), Samantha McLemore (6.7% of the portfolio), Baillie Gifford team (0.5% of the portfolio).
Superinvestors holding RPRX
5 of the investors tracked here report a position in their latest 13F filing.
- Pat Dorsey Dorsey Asset Management8.23% of portfolio · $141M · trimmed · Q3 2026
- Samantha McLemore Patient Capital Management6.71% of portfolio · $199.7M · trimmed · Q3 2026
- Baillie Gifford team Baillie Gifford & Co0.50% of portfolio · $534.1M · trimmed · Q3 2026
- Murray Stahl Horizon Kinetics0.26% of portfolio · $20.6M · added · Q3 2026
- Paul Tudor Jones Tudor Investment Corp0.14% of portfolio · $34.2M · trimmed · Q2 2026
Health Care companies of similar size
- BeOne MedicinesONC
- WatersWAT
- NateraNTRA
- IQVIA HoldingsIQV
- Revolution MedicinesRVMD
- BiogenBIIB
- GE HealthCare TechnologiesGEHC
- AlconALC
- Mettler-Toledo InternationalMTD
- CenteneCNC
- GenmabGMAB
- IlluminaILMN
Side by side:RPRX vs BIIB (Royalty Pharma plc vs Biogen)RPRX vs GEHC (Royalty Pharma plc vs GE HealthCare Technologies)RPRX vs RVMD (Royalty Pharma plc vs Revolution Medicines)RPRX vs ALC (Royalty Pharma plc vs Alcon)RPRX vs IQV (Royalty Pharma plc vs IQVIA Holdings)
All health care companies by market valueLargest companies in the United StatesAll stocks A–Z
Royalty Pharma plc (RPRX): questions and answers
What is RPRX's P/E ratio?
Royalty Pharma plc trades at 44.6× its last twelve months' earnings and 11.6× next year's expected earnings. At its fiscal year-ends over the past 6 years the P/E ranged from 11.1× to 395.2×, with a median of 24.2×.
What is RPRX's PEG ratio?
Royalty Pharma plc's PEG ratio is 2.10 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Royalty Pharma plc's market cap?
Royalty Pharma plc is valued at $39.27B at a share price of $68.30.
Is RPRX overvalued or undervalued?
Against its own history, RPRX is well above its usual price: the price is 121% above the $30.91 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is RPRX above its 200-week moving average?
Yes. RPRX is 86.5% above its 200-week average of $36.63. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Royalty Pharma plc growing?
Over the last five fiscal years Royalty Pharma plc's revenue grew 2.3% a year and its earnings per share 6.2% a year.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Royalty Pharma plc (RPRX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RPRX
Underlying data: Yahoo Finance; company filings with the SEC.